Pharmac To Reconsider Herceptin Funding
Media Release
03 April 2008
Pharmac To
Reconsider Herceptin Funding
The eight breast cancer
patients who took their case to the High Court seeking the
overturning of Pharmac’s funding decisions for the cancer
drug Herceptin can take some comfort from the High Court
decision that Pharmac must reconsider and consult over its
decision not to fund 12 months of Herceptin for women with
early breast cancer, says New Zealand First health
spokesperson Barbara Stewart.
“The ball is now back in Pharmac’s court.
“The court case will have been immensely stressful for all those involved and the review of this decision must not be dragged out any longer than is absolutely essential,” said Mrs Stewart.
ENDS